ABT 606 VS ACYCLOVIR FOR TREATMENT OF HERPES ZOSTER

待验证的假设是ABT-606在治疗VZV感染方面具有潜在的应用前景。这是一项阳性对照、双盲、双假、随机、四组、平行、多中心临床试验，研究对象为50岁及以上的活动性无并发症带状疱疹感染患者。符合条件的患者必须在出现带状疱疹/水疱后72小时内入组。研究分为两个阶段；急性评估期（1 ~ 28天）和随访期（29天）。大约400名符合入组标准的患者将以平衡的方式随机分配，以便每个治疗组随机分配100名患者。预计每个站点将招募2-10名患者。研究的总时间为6个月。这项研究的意义在于，ABT-606可能是一种有效和安全的替代阿昔洛韦治疗带状疱疹的药物。

The hypothesis to be tested is that ABT-606 has potential application in the treatment of VZV infections. This is a positive control, double-blind, double-dummy, randomized, four-arm, parallel, multicenter clinical trial in patients 50 years and older with active uncomplicated herpes zoster infection. To be eligible patients must enroll within 72 hours of the appearance of zosteriform rash/vesicles. The study is divided into two periods; the Acute Assessment Period (days 1-28) and the Follow-up Perod (days 29-end of study). Approximately 400 patients who satisfy the entry criteria will be randomized in a balanced fashion so that 100 patients are randomized to each treatment arm. It is expected that each site will enroll 2-10 patients. The total duration of the study is six months. The significance of this study is that ABT-606 may be an effective and safe alternative to acyclovir for the treatment of shingles.